Literature DB >> 8353248

Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.

D M Musher1, J E Groover, J M Rowland, D A Watson, J B Struewing, R E Baughn, M A Mufson.   

Abstract

The prevalence of immunity to Streptococcus pneumoniae in the adult population of the United States is unknown. In the study described herein, military recruits had anticapsular IgG antibody to only 15% of common pneumococcal serotypes, whereas working men and elderly men had IgG antibody to 33% and 34% of the common serotypes, respectively (P < .001). Among eight elderly subjects, the prevalence of IgG antibody to capsular polysaccharides increased from 30% to 78% after pneumococcal vaccination; 6 years thereafter, the rate of positive reactions had declined to 58% and IgG levels had declined substantially. With revaccination, IgG levels returned to within (+/-) 40% of the original postvaccination levels. IgM and IgG antibody appeared or began to increase in titer 6 days after vaccination; the rate and degree of response were the same after the first and second exposures. Since most individuals rapidly develop IgG antibody after colonization by S. pneumoniae and since IgG confers immunity, these data suggest that pneumonia is infrequent among healthy adults not because preexisting immunity is widespread but because--with colonization--an immune response develops rapidly, preceding specific events that might lead to infection. Our findings support recommended vaccination procedures and suggest that wider application in subsets of healthy younger adults should be considered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353248     DOI: 10.1093/clinids/17.1.66

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 2.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

3.  Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Authors:  Raymond E Biagini; Sonela A Schlottmann; Deborah L Sammons; Jerome P Smith; John C Snawder; Cynthia A F Striley; Barbara A MacKenzie; David N Weissman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

4.  Dexamethasone treatment has no effect on the formation of pneumococcal antibodies during community-acquired pneumonia.

Authors:  Suzan P van Mens; Sabine C A Meijvis; Jan C Grutters; Bart J M Vlaminckx; Willem J W Bos; Ger T Rijkers
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

5.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

6.  Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization.

Authors:  J N Weiser; R Austrian; P K Sreenivasan; H R Masure
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Measurement of pneumococcal capsular polysaccharide serotype-specific immunoglobulin G in human serum, a method for assigning weight-based units to proposed reference sera.

Authors:  K M Rudolph; A J Parkinson
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

8.  Mycoplasmas and non-gonococcal urethritis.

Authors:  P J Horner; D Taylor-Robinson
Journal:  Genitourin Med       Date:  1994-02

9.  Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone.

Authors:  Suzan P van Mens; Sabine C A Meijvis; Henrik Endeman; Heleen van Velzen-Blad; Douwe H Biesma; Jan C Grutters; Bart J M Vlaminckx; Ger T Rijkers
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

10.  Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Authors:  Ken B Waites; Kay C Canupp; Yu-Ying Chen; Michael J DeVivo; Moon H Nahm
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.